LRRK2 and Parkinson disease: A deeper understanding of LRRK2 dimerisation dynamics may also present a therapeutic opportunity to restore the balance between heterodimers and homodimers, potentially modulating disease progression in Parkinson’s patients with LRRK2-linked pathogenesis (Deyaert et al., 2017).